Genetic testing for exercise prescription and injury prevention: AIS-Athlome consortium-FIMS joint statement

Nicole Vlahovich; David Hughes; Lynn R Griffiths; Guan Wang; Yannis Pitsiladis; Fabio Pigozzi; Nobert Bachl; Nir Eynon

doi:10.1186/s12864-017-4185-5

Genetic testing for exercise prescription and injury prevention: AIS-Athlome consortium-FIMS joint statement

Nicole Vlahovich, David Hughes, Lynn R Griffiths, Guan Wang, Yannis Pitsiladis, Fabio Pigozzi, Nobert Bachl, Nir Eynon

Research output: Contribution to journal › Article › peer-review

Abstract

Background: There has been considerable growth in basic knowledge and understanding of how genes are influencing response to exercise training and predisposition to injuries and chronic diseases. On the basis of this knowledge, clinical genetic tests may in the future allow the personalization and optimization of physical activity, thus providing an avenue for increased efficiency of exercise prescription for health and disease. Results: This review provides an overview of the current status of genetic testing for the purposes of exercise prescription and injury prevention. As such there are a variety of potential uses for genetic testing, including identification of risks associated with participation in sport and understanding individual response to particular types of exercise. However, there are many challenges remaining before genetic testing has evidence-based practical applications; including adoption of international standards for genomics research, as well as resistance against the agendas driven by direct to consumer genetic testing companies. Here we propose a way forward to develop an evidence based approach to support genetic testing for exercise prescription and injury prevention. Conclusion: Based on current knowledge, there is no current clinical application for genetic testing in the area of exercise prescription and injury prevention, however the necessary steps are outlined for the development of evidence-based clinical applications involving genetic testing.

Original language	English
Journal	BMC Genomics
Volume	18
Issue number	S8
DOIs	https://doi.org/10.1186/s12864-017-4185-5
Publication status	Published - 15 Nov 2017

Bibliographical note

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Access to Document

10.1186/s12864-017-4185-5Licence: CC BY

s12864-017-4185-5.pdfFinal published version, 286 KBLicence: CC BY

Cite this

@article{299098dd98424e43939406d2c03809a8,

title = "Genetic testing for exercise prescription and injury prevention: AIS-Athlome consortium-FIMS joint statement",

abstract = "Background: There has been considerable growth in basic knowledge and understanding of how genes are influencing response to exercise training and predisposition to injuries and chronic diseases. On the basis of this knowledge, clinical genetic tests may in the future allow the personalization and optimization of physical activity, thus providing an avenue for increased efficiency of exercise prescription for health and disease. Results: This review provides an overview of the current status of genetic testing for the purposes of exercise prescription and injury prevention. As such there are a variety of potential uses for genetic testing, including identification of risks associated with participation in sport and understanding individual response to particular types of exercise. However, there are many challenges remaining before genetic testing has evidence-based practical applications; including adoption of international standards for genomics research, as well as resistance against the agendas driven by direct to consumer genetic testing companies. Here we propose a way forward to develop an evidence based approach to support genetic testing for exercise prescription and injury prevention. Conclusion: Based on current knowledge, there is no current clinical application for genetic testing in the area of exercise prescription and injury prevention, however the necessary steps are outlined for the development of evidence-based clinical applications involving genetic testing.",

author = "Nicole Vlahovich and David Hughes and Griffiths, {Lynn R} and Guan Wang and Yannis Pitsiladis and Fabio Pigozzi and Nobert Bachl and Nir Eynon",

note = "This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.",

year = "2017",

month = nov,

day = "15",

doi = "10.1186/s12864-017-4185-5",

language = "English",

volume = "18",

journal = "BMC Genomics",

issn = "1471-2164",

number = "S8",

}

TY - JOUR

T1 - Genetic testing for exercise prescription and injury prevention: AIS-Athlome consortium-FIMS joint statement

AU - Vlahovich, Nicole

AU - Hughes, David

AU - Griffiths, Lynn R

AU - Wang, Guan

AU - Pitsiladis, Yannis

AU - Pigozzi, Fabio

AU - Bachl, Nobert

AU - Eynon, Nir

N1 - This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PY - 2017/11/15

Y1 - 2017/11/15

N2 - Background: There has been considerable growth in basic knowledge and understanding of how genes are influencing response to exercise training and predisposition to injuries and chronic diseases. On the basis of this knowledge, clinical genetic tests may in the future allow the personalization and optimization of physical activity, thus providing an avenue for increased efficiency of exercise prescription for health and disease. Results: This review provides an overview of the current status of genetic testing for the purposes of exercise prescription and injury prevention. As such there are a variety of potential uses for genetic testing, including identification of risks associated with participation in sport and understanding individual response to particular types of exercise. However, there are many challenges remaining before genetic testing has evidence-based practical applications; including adoption of international standards for genomics research, as well as resistance against the agendas driven by direct to consumer genetic testing companies. Here we propose a way forward to develop an evidence based approach to support genetic testing for exercise prescription and injury prevention. Conclusion: Based on current knowledge, there is no current clinical application for genetic testing in the area of exercise prescription and injury prevention, however the necessary steps are outlined for the development of evidence-based clinical applications involving genetic testing.

AB - Background: There has been considerable growth in basic knowledge and understanding of how genes are influencing response to exercise training and predisposition to injuries and chronic diseases. On the basis of this knowledge, clinical genetic tests may in the future allow the personalization and optimization of physical activity, thus providing an avenue for increased efficiency of exercise prescription for health and disease. Results: This review provides an overview of the current status of genetic testing for the purposes of exercise prescription and injury prevention. As such there are a variety of potential uses for genetic testing, including identification of risks associated with participation in sport and understanding individual response to particular types of exercise. However, there are many challenges remaining before genetic testing has evidence-based practical applications; including adoption of international standards for genomics research, as well as resistance against the agendas driven by direct to consumer genetic testing companies. Here we propose a way forward to develop an evidence based approach to support genetic testing for exercise prescription and injury prevention. Conclusion: Based on current knowledge, there is no current clinical application for genetic testing in the area of exercise prescription and injury prevention, however the necessary steps are outlined for the development of evidence-based clinical applications involving genetic testing.

U2 - 10.1186/s12864-017-4185-5

DO - 10.1186/s12864-017-4185-5

M3 - Article

SN - 1471-2164

VL - 18

JO - BMC Genomics

JF - BMC Genomics

IS - S8

ER -

Genetic testing for exercise prescription and injury prevention: AIS-Athlome consortium-FIMS joint statement

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this